Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. Biogen markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis, FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy.
Company Growth (employees)
Type
Public
HQ
Cambridge, US
Founded
1978
Size (employees)
7,400 (est)
Website
biogen.com
Biogen was founded in 1978 and is headquartered in Cambridge, US

Key People/Management at Biogen

Michel Vounatsos

Michel Vounatsos

Chief Executive Officer
Michael Ehlers

Michael Ehlers

Executive Vice President
Paul McKenzie

Paul McKenzie

Executive Vice President
Ginger Gregory

Ginger Gregory

Executive Vice President and Chief Human Resources Officer
Chirfi Guindo

Chirfi Guindo

Executive Vice President and Head of Global Marketing, Market Access and Customer Innovation
Alfred Sandrock

Alfred Sandrock

Executive Vice President and Chief Medical Officer
Susan Alexander

Susan Alexander

Executive Vice President, Chief Legal, Corporate Services and Secretary
Jeffrey Capello

Jeffrey Capello

Executive Vice President and Chief Financial Officer

Biogen Office Locations

Biogen has an office in Cambridge
Cambridge, US (HQ)
225 Binney St
Show all (1)

Biogen Financials and Metrics

Biogen Financials

Biogen's revenue was reported to be $11.4 b in FY, 2016
USD

Revenue (Q1, 2017)

2.8 b

Net income (Q1, 2017)

747.5 m

EBIT (Q1, 2017)

1 b

Market capitalization (22-Dec-2017)

67.7 b

Cash (31-Mar-2017)

924 m
Biogen's current market capitalization is $67.7 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

6.9 b9.7 b10.8 b11.4 b

Revenue growth, %

40%11%6%

R&D expense

2 b

General and administrative expense

1.9 b
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

2.4 b2.5 b2.6 b2.6 b2.8 b2.7 b2.9 b3 b2.8 b

R&D expense

447.3 m417.2 m460.5 m490.7 m519.9 m437.3 m473.1 m529 m423.4 m

General and administrative expense

576.6 m570.4 m560.4 m491.9 m477.8 m497.3 m492.4 m462.7 m499.1 m

Operating expense total

1 b987.6 m1 b982.6 m997.7 m934.6 m965.5 m991.7 m922.5 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

602.6 m1.2 b1.3 b2.3 b

Accounts Receivable

824.4 m1.3 b1.2 b1.4 b

Inventories

659 m804 m893.4 m1 b

Current Assets

3.2 b4.7 b6.7 b8.7 b
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

863.2 m1.2 b1.5 b1.3 b4.1 b1.1 b1.4 b2.1 b924 m

Accounts Receivable

1 b1.1 b1.4 b1.3 b1.3 b1.4 b1.3 b1.5 b1.5 b

Inventories

715.9 m753.1 m825.3 m865.7 m918.9 m964.6 m996.4 m1 b921.6 m

Current Assets

3.9 b4.4 b5.3 b5.6 b9.3 b7.2 b7.4 b8.1 b6.9 b
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

1.9 b2.9 b3.6 b3.7 b

Depreciation and Amortization

688.2 m600.4 m682.7 m

Accounts Receivable

(130 m)(510 m)29 m(241.4 m)

Inventories

(240 m)(190 m)(170 m)(165.6 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

723.1 m856.1 m820.2 m924.8 m1 b969.2 m1 b1 b747.5 m

Accounts Receivable

1.3 b1.3 b1.4 b1.3 b1.5 b1.5 b

Inventories

865.7 m918.9 m964.6 m996.4 m1 b921.6 m

Accounts Payable

282.7 m251.2 m271.3 m225.9 m274 m316.4 m
USDY, 2017

Revenue/Employee

379.8 k

Financial Leverage

1.8 x
Show all financial metrics

Biogen Operating Metrics

Biogen's Training Provided, no. of people was reported to be 40 k in FY, 2016
FY, 2016

Training Provided, no. of people

40 k

Phase III Trials

2

Phase II Trials

10

Phase I Trials

4
Show all operating metrics

Biogen Market Value History

Biogen Median Salaries

Source: 109 public H-1B filings from Biogen

Biogen's Web-traffic and Trends

Biogen Online and Social Media Presence

Biogen News and Updates

Biogen, AbbVie and Regeneron set to gain from tax reform: analyst

With the New Year comes a new tax system in the U.S., and now many analysts and consultants are digging into how the GOP's reform will affect major pharma players. This week, Leerink Partners analysts are out with their picks for the large biotechs that will see the most benefit, and a few that migh…

Biogen set to raise $300M from New Year's price hikes, just enough to offset MS competition

Allergan, Teva and several other specialty pharmas weren't the only drug companies to raise prices Monday. Biogen also boosted the stickers on some of its key multiple sclerosis medications—just when analysts expected the franchise to lose sales to new rivals.

Combination Antibody Therapy Market is Anticipated to Register 14.2% CAGR through 2016 to 2024

Healthy R&D pipelines are leading towards higher product offerings and also propelling the growth of global combination antibody therapy market to a significant extent. Posted via Industry Today. Follow us on Twitter @IndustryToday

How can new launches mimic Keytruda, Harvoni and Opdivo? A new report has some ideas

In just a few years, pharma's top launches of 2014 have not only amassed huge sales but reshaped treatment, too—and they're now among the biggest launches ever. The names? No surprise: Gilead's hepatitis C treatment Harvoni, Merck's immuno-oncology therapy Keytruda and its head-to-head rival, Bristo…

Q3 Spinraza math confounds analysts as Biogen beats on both lines

Spinraza took center stage on Biogen’s third-quarter earnings call—in part because analysts couldn’t square their math on sales of the spinal muscular atrophy medication.

Rep. Cummings to Trump: It's time to force lower prices on Biogen's new MS drug Zinbryta

Rep. Elijah Cummings, D-Md., is urging President Donald Trump to twist some arms at Biogen. The biotech's new multiple sclerosis drug Zinbryta, developed with the help of taxpayer-funded research, costs too much, he argued, and Trump should use his power to push a price cut.
Show more

Biogen Company Life and Culture

You may also be interested in